Coloplast CEO urged to take action: Release the billions!

Medtech firm Coloplast is on a buying spree, but its purchases are too few and far between, according to industry sources. Pharmaceutical firms Novo Nordisk and Lundbeck have led the way so far.
Coloplast CEO Kristian Villumsen | Photo: Stine Bidstrup/ERH
Coloplast CEO Kristian Villumsen | Photo: Stine Bidstrup/ERH
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN

The wealthy and highly lucrative medtech firm Coloplast needs to let go of some of its caution, release the billions and acquire either new firms or technology, according to several industry actors.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading